Adagio Medical Posts Zero Third-Quarter Revenue as Cash Crisis Deepens
ADGM sits 16% above its 52-week low of $1.5 on light trading volume (0.4× avg).
Summary
Adagio Medical reported $0.00 in third-quarter revenue, confirming the commercial engine has stalled while the company burns through a dwindling cash pile, and posted a third-quarter loss per share of $5.13. The zero top line lands after a brutal stretch: the board opened a strategic alternatives process including a possible sale on September 23, alongside a 58% workforce reduction, and the company has already executed a 1-for-30 reverse split on November 6 to hold its Nasdaq listing. Cash stood at $7.7M at the last 10-Q with a going concern warning and runway only into Q4 2026, so a quarter with no revenue sharpens the liquidity clock considerably. Days after the reverse split the company filed a new proxy seeking approval for another reverse split of up to 1-for-1,000 — a sign management sees continued listing pressure rather than a fix. The strategic alternatives process is the live event; any announcement of a buyer, merger partner, or financing is what changes the story from here.
At the time of this announcement, ADGM was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.50 to $50.70. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.